Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1

R. Bures, A. Gaitan, T. Zhu, C. Graziosi, K. M. McGrath, J. Tartaglia, P. Caudrelier, R. El Habib, M. Klein, A. Lazzarin, D. M. Stablein, M. Deers, L. Corey, M. L. Greenberg, D. H. Schwartz, D. C. Montefiori

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Antibodies generated by candidate HIV-1 vaccines in a phase I clinical trial were assessed for neutralizing activity with a panel of eight well-characterized, genetically diverse clade B primary isolates having an R5 phenotype. The vaccines consisted of one of three different recombinant canarypox vectors expressing membrane-anchored HIV-1MNgp120 (ALVAC vCP205, vCP1433, and vCP1452) followed by boosting with a soluble gp160 hybrid consisting of MNgp120 and the majority of gp41 from strain IIIB. Serum samples from a subset of volunteers in each arm of the trial, containing moderate to high titers of neutralizing antibodies to HIV-1 MN, were analyzed. Competition assays with peptides revealed that the majority of neutralizing activity was specific for the MN-V3 loop. Despite MN-specific neutralization titers that sometimes exceeded 1:500, no neutralization of primary isolates was detected and, in some cases, mild infection enhancement was observed. In addition, little or no neutralization of the HIV-1 IIIB heterologous T cell line-adapted strain of virus was detected. These results reinforce the notion that monovalent HIV-1 ENV is a poor immunogen for generating cross-reactive neutralizing antibodies.

Original languageEnglish
Pages (from-to)2019-2035
Number of pages17
JournalAIDS Research and Human Retroviruses
Volume16
Issue number18
DOIs
Publication statusPublished - Dec 10 2000

Fingerprint

Membrane Glycoproteins
HIV-1
Immunization
Glycoproteins
Antibodies
Neutralizing Antibodies
AIDS Vaccines
Clinical Trials, Phase I
Volunteers
Vaccines
Viruses
T-Lymphocytes
Phenotype
Cell Line
Peptides
Membranes
Infection
Serum

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. / Bures, R.; Gaitan, A.; Zhu, T.; Graziosi, C.; McGrath, K. M.; Tartaglia, J.; Caudrelier, P.; El Habib, R.; Klein, M.; Lazzarin, A.; Stablein, D. M.; Deers, M.; Corey, L.; Greenberg, M. L.; Schwartz, D. H.; Montefiori, D. C.

In: AIDS Research and Human Retroviruses, Vol. 16, No. 18, 10.12.2000, p. 2019-2035.

Research output: Contribution to journalArticle

Bures, R, Gaitan, A, Zhu, T, Graziosi, C, McGrath, KM, Tartaglia, J, Caudrelier, P, El Habib, R, Klein, M, Lazzarin, A, Stablein, DM, Deers, M, Corey, L, Greenberg, ML, Schwartz, DH & Montefiori, DC 2000, 'Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1', AIDS Research and Human Retroviruses, vol. 16, no. 18, pp. 2019-2035. https://doi.org/10.1089/088922200750054756
Bures, R. ; Gaitan, A. ; Zhu, T. ; Graziosi, C. ; McGrath, K. M. ; Tartaglia, J. ; Caudrelier, P. ; El Habib, R. ; Klein, M. ; Lazzarin, A. ; Stablein, D. M. ; Deers, M. ; Corey, L. ; Greenberg, M. L. ; Schwartz, D. H. ; Montefiori, D. C. / Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. In: AIDS Research and Human Retroviruses. 2000 ; Vol. 16, No. 18. pp. 2019-2035.
@article{19a713901c5e4cf599908a3433f00526,
title = "Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1",
abstract = "Antibodies generated by candidate HIV-1 vaccines in a phase I clinical trial were assessed for neutralizing activity with a panel of eight well-characterized, genetically diverse clade B primary isolates having an R5 phenotype. The vaccines consisted of one of three different recombinant canarypox vectors expressing membrane-anchored HIV-1MNgp120 (ALVAC vCP205, vCP1433, and vCP1452) followed by boosting with a soluble gp160 hybrid consisting of MNgp120 and the majority of gp41 from strain IIIB. Serum samples from a subset of volunteers in each arm of the trial, containing moderate to high titers of neutralizing antibodies to HIV-1 MN, were analyzed. Competition assays with peptides revealed that the majority of neutralizing activity was specific for the MN-V3 loop. Despite MN-specific neutralization titers that sometimes exceeded 1:500, no neutralization of primary isolates was detected and, in some cases, mild infection enhancement was observed. In addition, little or no neutralization of the HIV-1 IIIB heterologous T cell line-adapted strain of virus was detected. These results reinforce the notion that monovalent HIV-1 ENV is a poor immunogen for generating cross-reactive neutralizing antibodies.",
author = "R. Bures and A. Gaitan and T. Zhu and C. Graziosi and McGrath, {K. M.} and J. Tartaglia and P. Caudrelier and {El Habib}, R. and M. Klein and A. Lazzarin and Stablein, {D. M.} and M. Deers and L. Corey and Greenberg, {M. L.} and Schwartz, {D. H.} and Montefiori, {D. C.}",
year = "2000",
month = "12",
day = "10",
doi = "10.1089/088922200750054756",
language = "English",
volume = "16",
pages = "2019--2035",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "18",

}

TY - JOUR

T1 - Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1

AU - Bures, R.

AU - Gaitan, A.

AU - Zhu, T.

AU - Graziosi, C.

AU - McGrath, K. M.

AU - Tartaglia, J.

AU - Caudrelier, P.

AU - El Habib, R.

AU - Klein, M.

AU - Lazzarin, A.

AU - Stablein, D. M.

AU - Deers, M.

AU - Corey, L.

AU - Greenberg, M. L.

AU - Schwartz, D. H.

AU - Montefiori, D. C.

PY - 2000/12/10

Y1 - 2000/12/10

N2 - Antibodies generated by candidate HIV-1 vaccines in a phase I clinical trial were assessed for neutralizing activity with a panel of eight well-characterized, genetically diverse clade B primary isolates having an R5 phenotype. The vaccines consisted of one of three different recombinant canarypox vectors expressing membrane-anchored HIV-1MNgp120 (ALVAC vCP205, vCP1433, and vCP1452) followed by boosting with a soluble gp160 hybrid consisting of MNgp120 and the majority of gp41 from strain IIIB. Serum samples from a subset of volunteers in each arm of the trial, containing moderate to high titers of neutralizing antibodies to HIV-1 MN, were analyzed. Competition assays with peptides revealed that the majority of neutralizing activity was specific for the MN-V3 loop. Despite MN-specific neutralization titers that sometimes exceeded 1:500, no neutralization of primary isolates was detected and, in some cases, mild infection enhancement was observed. In addition, little or no neutralization of the HIV-1 IIIB heterologous T cell line-adapted strain of virus was detected. These results reinforce the notion that monovalent HIV-1 ENV is a poor immunogen for generating cross-reactive neutralizing antibodies.

AB - Antibodies generated by candidate HIV-1 vaccines in a phase I clinical trial were assessed for neutralizing activity with a panel of eight well-characterized, genetically diverse clade B primary isolates having an R5 phenotype. The vaccines consisted of one of three different recombinant canarypox vectors expressing membrane-anchored HIV-1MNgp120 (ALVAC vCP205, vCP1433, and vCP1452) followed by boosting with a soluble gp160 hybrid consisting of MNgp120 and the majority of gp41 from strain IIIB. Serum samples from a subset of volunteers in each arm of the trial, containing moderate to high titers of neutralizing antibodies to HIV-1 MN, were analyzed. Competition assays with peptides revealed that the majority of neutralizing activity was specific for the MN-V3 loop. Despite MN-specific neutralization titers that sometimes exceeded 1:500, no neutralization of primary isolates was detected and, in some cases, mild infection enhancement was observed. In addition, little or no neutralization of the HIV-1 IIIB heterologous T cell line-adapted strain of virus was detected. These results reinforce the notion that monovalent HIV-1 ENV is a poor immunogen for generating cross-reactive neutralizing antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0034634910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034634910&partnerID=8YFLogxK

U2 - 10.1089/088922200750054756

DO - 10.1089/088922200750054756

M3 - Article

VL - 16

SP - 2019

EP - 2035

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 18

ER -